Selective internal radiation therapy

Series
Radiotherapy
Status
Published
Date
Number of report
072

Ask the expert

(we accept only company emails)

The report presents a summary of reimbursement situation for selective internal radiation therapy in Europe.

Sample pages are provided for an older version of the report. Before delivery to the client, the report is updated to the current state (e.g., 2022 coding, tariffs, and policy considerations). 

The following indications will be considered:

  • Primary liver cancer (hepatocellular carcinoma);
  • Metastatic liver cancer.

Different types of microspheres for SIRT will be covered in the report, including those use the radionuclide yttrium-90 and based on the radionuclide holmium-166.

The only reimbursement within public / statutory health insurance systems is considered. The results will be provided for hospital settings.

Report includes essential information about reimbursement and national funding, including:

  • Brief overview of reimbursement system for medical devices
  • Procedure coding for technology
  • Diagnosis coding
  • Payment mechanism for technology
  • Reimbursement tariffs for technology
  • Restrictions in indications or scenarios for use of technology
  • Policy considerations by payers and policy-makers about technology

Reimbursement information is provided for the following geographies:

  • Austria
  • Belgium
  • Denmark
  • England (UK)
  • France
  • Germany
  • Italy
  • Netherlands
  • Norway
  • Sweden
  • Switzerland

It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.

Manufacturers of treatment of selective internal radiation therapy (SIRT):

  • Bio-Rad (Bio-Rex, Aminex)
  • BTG (TheraSphere)
  • Sirtex (Sir-spheres)
  • Terumo (QuiremScout, QuiremSpheres)

Table of content is not available at the moment. Report is still ongoing.

23

Jun 2022

On May 31, 2022, Regional Cancer Centers collaboration (RCC) updated the national care program for breast cancer. New and updated recommendations concerned genetic testing, molecular diagnostic, de-escalation of surgical treatment for certain patient groups, radiotherapy regimens, and pharmacotherapy. A new chapter was added on breast cancer in men.

Read more

17

Jun 2022

On May 31, 2022, it was announced by the Ministry of Health that the Council of Ministers authorized the distribution of almost €400 million for the renovation of high-tech equipment in the National Health System (SNS) through the High-End Technology Equipment Investment Plan (INVEAT) of the SNS.

Read more

26

May 2022

In April 2022, the Dutch Healthcare Institute (Zorginstituut Nederland, ZIN) announced two projects which received a subsidy under the "Subsidy scheme for promising care" in 2022 for research of a transcatheter tricuspid valve repair in severe leakage of the tricuspid valve and precision radiation in epilepsy. In total, five projects will receive a subsidy in 2022.

Read more

06

May 2022

In Q1 of 2022, Health Technology Wales (HTW) published one MedTech-related guidance on transcranial magnetic stimulation in depression treatment. A total of eleven Topic Exploration Reports (TERs) were released in Q1. Based on the TERs conclusions, HTW's Assessment Group decided to proceed with developing an Evidence Appraisal Report (EAR) and Guidance on one topic only - radiofrequency renal denervation for the treatment of resistant hypertension.

Read more

26

Apr 2022

The revised EBM (German Uniform Evaluation Standard) catalog came into force on April 1, 2022. The most significant changes concern the introduction of new additional flat rates for the observation and care of patients who are given certain medications, adjustment of EBM reproductive medicine definitions, and inclusion of several new codes for PET and PET/CT.

Read more
(we accept only company emails)